Detailed Information
Cited 0 time in 
Cited 10 time in 
Cited 10 time in
Metadata Downloads
Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak
- Authors
- Lee S.H.; Yim J.-J.; Kim H.J.; Shim T.S.; Seo H.S.; Cho Y.S.; Lee H.-K.; Lee Y.M.; Lee E.J.; Lew W.J.
- Issue Date
- 2012
- Keywords
- Antibiotic prophylaxis; drug toxicity; multidrug-resistant tuberculosis; rifampicin; tuberculosis
- Citation
- Epidemiology and Infection, v.140, no.6, pp 1028 - 1035
- Pages
- 8
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Epidemiology and Infection
- Volume
- 140
- Number
- 6
- Start Page
- 1028
- End Page
- 1035
- ISSN
- 0950-2688
1469-4409
- Abstract
- We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+/IGRA+ (n=101), TST+/IGRA- (n=22), TST-/IGRA+ (n=16), and TST-/IGRA- (n=41). RFP treatment (4 months) was prescribed only to the TST+/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST+/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis. © 2011 Cambridge University Press.
- Files in This Item
- There are no files associated with this item.
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Lee, Seung Heon
- Ansan Hospital (Department of Pulmonary, Allergy, and Critical Care Medicine, Ansan Hospital)